500 patients67,039 observations150 daysLIVE

Patient P-03346

Synthetic patientONX-7 · Day 112 · 35–44 · M · baseline S17Open companion preview
Therapy response
Improving
Tolerance
Deteriorating
GI state
Deteriorating
Inflammatory state
Stable
Nutritional resilience
Declining
Discontinuation risk
47%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S17
  2. Day 23 Trajectory diverged from predictionObserved response fell below the model's expected path.
  3. Day 102 GI-04 recommendedGI Support Protocol GI-04
  4. Day 103 Patient acceptedStarted GI-04 in the companion
  5. Day 111 GI symptom burden −15% vs expectedGI Support Protocol GI-04
  6. Day 117 Tolerance state changedUnstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 23.

Primary contributors, last 14 days
  • GI instability+6
  • Inflammatory activity+4
  • Nutritional resilience-4
  • Toxicity+4
  • Treatment adherence-3

What helped?

  • GI Support Protocol GI-04Day 102
    Result: symptom burden −15%
LIFE OS recommendation
Dosing / Timing Recommendation DT-01
60%
probability of meaningful tolerance improvement
  • 284 similar trajectories
  • 80% showed improvement
  • median effect visible after 5 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure
  • Butyrate / short-chain fatty acid production 80
    • MicrobiomeButyrate capacity 39/100
    • MicrobiomeF. prausnitzii depleted
    • Daily logFibre intake low in recent food logs
  • Inflammatory signalling 50
    • DNAIL6 -174 variant raises baseline inflammatory tone
    • BloodInflammatory load index 49
  • Autonomic recovery 25
    • WearableResting HR 77 bpm
  • Mucosal barrier integrity 20
    • Daily logGI symptom score 57 and rising
DNA
Fictional pharmacogenomic panel
  • IL6 -174 G/C
    Higher inflammatory tone
  • CYP2D6 Normal metabolizer
    Expected exposure
Microbiome
Shannon diversity 2.6 · butyrate capacity 39/100
  • Akkermansia muciniphilaNormal
  • Faecalibacterium prausnitziiLow
  • Bacteroides fragilisNormal
  • Bifidobacterium longumLow
  • EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
HRV
47 ms
Sleep
7.0 h
Steps
3,563
Resting HR
75 bpm
Daily log: GI score 57, nutritional resilience 43, adherence 89.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview
What to eat
  • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
  • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
  • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
  • Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
  • Track each bowel movement today: time, stool form, urgency, overnight waking
  • A 15-minute walk after lunch
  • Keep the sleep window steady
  • Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
  • Take the scheduled dose as agreed with your care team
  • Electrolyte solution, one sachet after any loose stool
  • Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

PatientSimilarityBaselineInterventionOutcomeResponse today
P-0322148%S06GI-04no change64
P-0329246%S1462
P-0340544%S1662
P-0312043%S1461
P-0316040%S1863
P-0337840%S1059
P-0321838%S2056
P-0302737%S2062
P-0337937%S12GI-04improved51
P-0320736%S0461
P-0307435%S0160
P-0320035%S1659